Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD

The Journal of clinical endocrinology and metabolism1 Jul 2003Cited by 389 (Europe PMC)

PMID12843147DOI10.1210/jc.2002-021545PepBankPUB-12843147

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced mean postprandial glucose versus placebo in study A.
In plain wordsIn patients with type 2 diabetes, exenatide lowered postmeal glucose versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucose
Study
n = 24
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1 micro g/kg twice daily · subcutaneous · 5 dAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in mean postprandial circulating concentrations of glucose, insulin, and glucagon occurred following treatment with AC2993.
2 context sentences(design, population, supporting numbers)
Summary · context
In study A, 24 subjects received sc injections of study medication (0.1 micro g/kg AC2993 or placebo) twice daily with meals for 5 d.
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314701
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced mean postprandial insulin versus placebo in study A.
In plain wordsIn patients with type 2 diabetes, exenatide lowered postmeal insulin versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial insulin
Study
n = 24
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1 micro g/kg twice daily · subcutaneous · 5 dAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in mean postprandial circulating concentrations of glucose, insulin, and glucagon occurred following treatment with AC2993.
2 context sentences(design, population, supporting numbers)
Summary · context
In study A, 24 subjects received sc injections of study medication (0.1 micro g/kg AC2993 or placebo) twice daily with meals for 5 d.
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314702
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced mean postprandial glucagon versus placebo in study A.
In plain wordsIn patients with type 2 diabetes, exenatide lowered postmeal glucagon versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucagon
Study
n = 24
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1 micro g/kg twice daily · subcutaneous · 5 dAs given in this study (human).
Source sentences
Summary
Statistically significant reductions in mean postprandial circulating concentrations of glucose, insulin, and glucagon occurred following treatment with AC2993.
2 context sentences(design, population, supporting numbers)
Summary · context
In study A, 24 subjects received sc injections of study medication (0.1 micro g/kg AC2993 or placebo) twice daily with meals for 5 d.
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314703
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, a single exenatide dose reduced fasting glucose during the subsequent 8-h period in study B.
In plain wordsIn patients with type 2 diabetes, a single exenatide dose lowered fasting glucose versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting plasma glucose
Study
n = 13
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 0.1, or 0.2 micro g/kg · subcutaneousAs given in this study (human).
Source sentences
Summary
In study B, 13 subjects receiving a single dose of study medication (0.05, 0.1, or 0.2 micro g/kg AC2993 or placebo) following an overnight fast had reduced fasting plasma glucose concentrations during the subsequent 8-h period.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314704
05HumanNon-randomized trialMechanism
In patients with type 2 diabetes, glucose and insulin profiles during exenatide treatment were consistent with glucose-dependent insulinotropism.
In plain wordsIn patients with type 2 diabetes, exenatide glucose and insulin profiles supported glucose-dependent insulin release.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGlucose-dependent insulinotropism
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The relative glucose and insulin concentration profiles were consistent with glucose-dependent insulinotropism.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314705
06HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes, exenatide was well tolerated.
In plain wordsIn patients with type 2 diabetes, exenatide was well tolerated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
AC2993 was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314706
07HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes receiving exenatide, mild transient headache was among the main adverse events.
In plain wordsIn patients with type 2 diabetes receiving exenatide, mild temporary headache was a main adverse event.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedHeadache
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Mild transient headache, nausea, and vomiting were the main adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314707
08HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes receiving exenatide, mild transient nausea was among the main adverse events.
In plain wordsIn patients with type 2 diabetes receiving exenatide, mild temporary nausea was a main adverse event.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Mild transient headache, nausea, and vomiting were the main adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314708
09HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes receiving exenatide, mild transient vomiting was among the main adverse events.
In plain wordsIn patients with type 2 diabetes receiving exenatide, mild temporary vomiting was a main adverse event.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedVomiting
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Mild transient headache, nausea, and vomiting were the main adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes.
Report a problemFND-1284314709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3Results postedNCT00650546

Role of Exenatide in NASH-a Pilot Study

Indiana Universityn = 8Aug 2006 to Aug 2010

Nonalcoholic Fatty Liver Disease

Trial page ClinicalTrials.govUpdated 11 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.